Contact the Editorial Desk

Editorial correspondence

Research Peptides US takes corrections seriously: a citation quoted inaccurately, a trial that has since published new results, a regulatory status update, or a peer-reviewed study on any of the five compounds that should be added to the references page. This is the single most useful class of message this desk receives, and every one is read.

The fastest-actioned submissions specify the exact page, the exact passage in question, and a supporting reference — a DOI or PubMed identifier wherever possible — so the proposed change can be verified against its source before anything is edited.

Editorial mailbox: editors@researchpeptidesus.com

What this desk cannot do

So no message goes unanswered for the wrong reason: Research Peptides US is a literature digest, not a clinical service or a vendor, so it cannot advise on human use of any compound discussed here, suggest a dose or schedule for any individual, evaluate whether a cited trial's findings apply to a specific person's situation, or sell, source, or help locate any compound from any supplier. It cannot advise athletes on anti-doping status for any compound.

Tirzepatide is a prescription medicine. Retatrutide is investigational and not legally available outside clinical trials. BPC-157 and KPV are unregulated research chemicals with no approved human use. Readers seeking medical guidance should consult a licensed clinician. Responses to editorial correspondence are not guaranteed and may be delayed.